MedTrace Logo

Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells

NCT02638714 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-03-17

No results posted yet for this study

Summary

A single arm, single center trial to assess the safety and efficacy of restoring function in damaged optic nerves using autologous purified populations of bone-marrow derived stem cells (BM-SCs) through a 24 month follow up period.

Conditions

  • Optic Neuropathy

Interventions

BIOLOGICAL

Stem Cells

Intervention: Transplantation of autologous purified stem cells

Sponsors & Collaborators

  • Stem Cells Arabia

    lead OTHER

Principal Investigators

  • Adeeb AlZoubi, PhD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2021-09-01
Completion
2021-10-01

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02638714 on ClinicalTrials.gov